Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (1070)	4/19/1999 9:27:00 PM
From: Intrepid1	Respond to of 1185

From the original Hoffman Release... under the terms of this agreement, Roche has paid Nortran a fee for the exclusive option to a worldwide (except for the ASEAN nations) licence to these compounds. If Roche exercises its option, Nortran will receive a licence fee as well as milestone payments upon reaching certain stages of development and certain sales levels of a new drug. The maximum amount of such payments will be $86.5-million (U.S.). In addition, Roche will pay Nortran a royalty on sales of any product coming from the program. There is nowhere in today's release where it says Hoffman will exercise its option. All the release says is the option will expire on or before June 15, 1999. This is a purposefully vague news release.Can anyone here tell me with any degree ofcertainty whether or not Hoffman is going to exercise its option and develop the drug? etc.

To: David Culver who wrote (1070)	4/20/1999 10:53:00 AM
From: BioInv	Respond to of 1185

Dave. How much have they put in so far?. Is this a low cost way to keep their options open for a few months.

To: David Culver who wrote (1070)	4/21/1999 11:10:00 PM
From: Charles Salski	Read Replies (1) \| Respond to of 1185

Hi David, Copied this from another chat group stockhouse.com Symbol: V.NRT Last Trade: 0.950 (-0.040) Nortran Pharmaceuticals Inc. Posted By Subject PostTime (EST) Post ID harbin2 Hoffman-Roche 4/16/99 / 11:27:02 AM 230441 << Previous Thread Next Thread >> The reason Hoffman didn't exercise their option on the 3 anti-arrythmic compounds by the end of March is because they are now considering licencing Nortran's entire anti-arrythmic program which I believe numbers around three hundred compounds. How long the negotiations will take on this one is anyone's guess. These pharmaceutical giants move at glacial speed, but apparently they are very interested. Just because the stock price is sagging doesn't mean the news is bad, people are just impatient which is understandable. Any comments anyone??? Regards, Charles